We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

29 hedge funds and large institutions have $123M invested in Sinovac Biotech, Ltd in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

4% more funds holding

Funds holding: 28 → 29 (+1)

77% less capital invested

Capital invested by funds: $527M → $123M (-$404M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.3K
2
Morgan Stanley
Morgan Stanley
New York
+$660

Top Sellers

Rank Fund Capital Flow
1
FIM
Freedom Investment Management
Connecticut
-$908
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$78.4M – – –
VC
2
Vivo Capital
California
$38.2M – – –
NAH
3
Neumann Advisory (HK)
Hong Kong
$2.04M – – –
State Street
4
State Street
Massachusetts
$1.82M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$1.54M – – –
YMRC
6
Yorktown Management & Research Company
Virginia
$485K – – –
Skandinaviska Enskilda Banken (SEB)
7
Skandinaviska Enskilda Banken (SEB)
Sweden
$259K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$179K – – –
FIM
9
Freedom Investment Management
Connecticut
$115K -$908 -140 -0.8%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$108K +$1.3K +200 +1%
UBS Group
11
UBS Group
Switzerland
$59K – – –
Northern Trust
12
Northern Trust
Illinois
$55K – – –
Morgan Stanley
13
Morgan Stanley
New York
$26K +$660 +100 +3%
JP Morgan Chase
14
JP Morgan Chase
New York
$19K – – –
Wells Fargo
15
Wells Fargo
California
$19K – – –
FGAM
16
Financial Gravity Asset Management
Texas
$6K – – –
HI
17
Harbour Investments
Wisconsin
$1K – – –

SVA Hedge Fund Activity: Q3 2021 in Review

29 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2021, worth a combined $123M — down 77% from $527M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SVA positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $1.3K. The largest seller was Freedom Investment Management, cutting an estimated $908.

  • 29 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2021, up from 28 in Q2 2021.
  • Funds reported $123M of Sinovac Biotech, Ltd stock for Q3 2021, down 77% quarter-over-quarter.
  • 2 funds opened new Sinovac Biotech, Ltd positions in Q3 2021 and 0 closed out, a net change of +2 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q3 2021 was Susquehanna International Group, an estimated $1.3K added.
  • The largest Sinovac Biotech, Ltd seller in Q3 2021 was Freedom Investment Management, an estimated $908 sold.

Based on aggregated 13F filings for Q3 2021.